The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of
patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can …

Background Inhaled corticosteroids (ICS) are anti‐inflammatory drugs that have proven
benefits for people with worsening symptoms of chronic obstructive pulmonary disease …

Background Inhaled corticosteroids have been used in patients with chronic obstructive
pulmonary disease (COPD), but the potential benefits of their use in triple therapy are not …

Background Early descriptions of patients admitted to hospital during the COVID-19
pandemic showed a lower prevalence of asthma and chronic obstructive pulmonary disease …

Clin Microbiol Infect 2011; 17 (Suppl. 6): E1–E59 Abstract This document is an update of
Guidelines published in 2005 and now includes scientific publications through to May 2010 …

Background The long-term natural history of chronic obstructive pulmonary disease (COPD)
in terms of successive severe exacerbations and mortality is unknown. Methods The authors …

Background Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in
patients with chronic obstructive pulmonary disease (COPD). It is unclear whether the risk of …

Rationale: Exacerbations of chronic obstructive pulmonary disease (COPD) and responses
to treatment are heterogeneous. Objectives: Investigate the usefulness of blood eosinophils …

Inhaled corticosteroids (ICSs) are indicated for the prevention of exacerbations in COPD;
however, a significant proportion of patients at low risk of exacerbations are treated with …

Background Chronic respiratory disease and inhaled corticosteroid (ICS) therapy for chronic
obstructive pulmonary disease (COPD) increase the risk of pneumonia. Few data are …